ישראל - עברית - Ministry of Health

padagis israel pharmaceuticals ltd, israel - mebeverine hydrochloride - טבליה - mebeverine hydrochloride 135 mg - mebeverine - mebeverine - irritable bowel syndrome and conditions included in this group such as: chronic irritable colon, gastro- intestinal spasm secondary to organic diseases

ישראל - עברית - Ministry of Health

pharmalogic ltd - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg / 1 ml - fulvestrant

ישראל - עברית - Ministry of Health

pharmalogic ltd - atosiban as acetate - תרכיז להכנת תמיסה לאינפוזיה - atosiban as acetate 7.5 mg/ml - atosiban

ישראל - עברית - Ministry of Health

pharmalogic ltd - atosiban as acetate - תמיסה להזרקה - atosiban as acetate 7.5 mg/ml - atosiban

ישראל - עברית - Ministry of Health

pharmalogic ltd - atosiban as acetate - תרכיז להכנת תמיסה לאינפוזיה - atosiban as acetate 7.5 mg/ml - atosiban

ישראל - עברית - Ministry of Health

pharmalogic ltd - terlipressin acetate - תמיסה להזרקה - terlipressin acetate 0.2 mg/ml - terlipressin

ישראל - עברית - Ministry of Health

pharmalogic ltd - pemetrexed as disodium - תרכיז להכנת תמיסה לאינפוזיה - pemetrexed as disodium 25 mg / 1 ml - pemetrexed

ישראל - עברית - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b

ישראל - עברית - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob